{"filing":{"accession_number":"0001193125-26-281817","cik":"0001815442","ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"d62555d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm"},"events":[{"id":13699,"run_id":12167,"accession_number":"0001193125-26-281817","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Kymera announced completion of enrollment in the Phase 2b BROADEN2 trial of KT-621 for atopic dermatitis ahead of schedule, with topline data accelerated to year-end 2026 (six months earlier than prior guidance) and Phase 3 initiation planned for mid-2027. This material clinical development milestone affects investor assessment of the company's pipeline progress and regulatory trajectory.","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":10915,"accession_number":"0001193125-26-281817","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces completion of enrollment in the Phase 2b BROADEN2 trial of KT-621 for atopic dermatitis, with topline data accelerated to year-end 2026 (six months ahead of prior guidance) and Phase 3 initiation planned for mid-2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company's lead program, affecting investor assessment of pipeline progress and regulatory pathway timing, but does not fit the specific operational categories (workforce reduction, restructuring) or other defined event types. The disclosure is clearly operational/strategic in nature rather than financial, governance, legal, or existential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T11:11:41.434684+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10916,"accession_number":"0001193125-26-281817","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Kymera announced completion of enrollment in the BROADEN2 Phase 2b trial of KT-621 ahead of schedule, with topline data accelerated to year-end 2026 (six months earlier than prior guidance) and Phase 3 initiation planned for mid-2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the company's pipeline progress and regulatory trajectory, but it does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other named event types—it is a clinical/operational milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T11:11:41.434684+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10915,"accession_number":"0001193125-26-281817","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces completion of enrollment in the Phase 2b BROADEN2 trial of KT-621 for atopic dermatitis, with topline data accelerated to year-end 2026 (six months ahead of prior guidance) and Phase 3 initiation planned for mid-2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company's lead program, affecting investor assessment of pipeline progress and regulatory pathway timing, but does not fit the specific operational categories (workforce reduction, restructuring) or other defined event types. The disclosure is clearly operational/strategic in nature rather than financial, governance, legal, or existential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T11:11:41.434684+00:00","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-06-25"},{"id":10916,"accession_number":"0001193125-26-281817","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Kymera announced completion of enrollment in the BROADEN2 Phase 2b trial of KT-621 ahead of schedule, with topline data accelerated to year-end 2026 (six months earlier than prior guidance) and Phase 3 initiation planned for mid-2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the company's pipeline progress and regulatory trajectory, but it does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other named event types—it is a clinical/operational milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T11:11:41.434684+00:00","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-06-25"}]}